From: Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy
Inclusion criteria | Exclusion criteria |
---|---|
Age between 20 and 75 years | History of kidney transplantation |
Type 2 diabetes using a glucose-lowering agent or insulin | Advanced congestive heart failure (≥ NYHA class III) |
Estimated GFR by the IDMS MDRD equation ≥30 ml/min/1.73 m2 | Uncontrolled arrhythmia |
More than two UACR ≥30 mg/g or UPCR ≥ 300 mg/g in the most recent 6 months | Advanced liver cirrhosis (Child-Pugh class C) |
Blood pressure ≤140/90 mmHg without any additional antihypertensive medications in the most recent 3 months | History of bleeding diathesis |
Active infection or uncontrolled inflammatory disorders | |
History of cerebrovascular accident or myocardial infarction | |
Current use of an anticoagulant | |
Current use of more than two antiplatelet agents | |
Advanced malignancy (life expectancy ≤6 months) | |
Uncontrolled diabetes (HbA1C >10%) | |
Severe anemia (hemoglobin <8.0 g/dL) | |
Pregnancy or lactation | |
Genetic disease including galactose intolerance, lactose deficiency, and glucose-galactose malabsorption |